The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy.